The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 billion. The midpoint suggests a 35% increase in sales for the full year.

Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Tennis star Serena Williams' candor about her GLP-1 use may help dispel the pesky health inaccuracy that weight loss is a ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement ...

A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite.

Tennis champion Serena Williams has divided the internet after revealing she’s been using a GLP-1 weight loss drug. The ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...

Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how ...